Literature DB >> 11502172

A structural model for the ternary cleavable complex formed between human topoisomerase I, DNA, and camptothecin.

J E Kerrigan1, D S Pilch.   

Abstract

Using the X-ray crystal structure of the human topoisomerase I (TOP1)-DNA cleavable complex, we have developed a general model for the ternary drug-DNA-TOP1 cleavable complex formed with camptothecin (CPT) and its analogues. This model has the drug intercalated between the -1 and +1 base pairs, with the E-ring pointing into the minor groove and the A-ring directed toward the major groove. The ternary complex is stabilized by an array of hydrogen bonding and hydrophobic interactions between the drug and both the enzyme and the DNA. Significantly, the proposed model is consistent with the current body of experimental mutation, cross-linking, and structure-activity data. In addition, the model reveals potential sites of interaction that can provide a rational basis for the design of next generation compounds as well as for de novo drug design.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11502172     DOI: 10.1021/bi010913l

Source DB:  PubMed          Journal:  Biochemistry        ISSN: 0006-2960            Impact factor:   3.162


  13 in total

1.  The mechanism of topoisomerase I poisoning by a camptothecin analog.

Authors:  Bart L Staker; Kathryn Hjerrild; Michael D Feese; Craig A Behnke; Alex B Burgin; Lance Stewart
Journal:  Proc Natl Acad Sci U S A       Date:  2002-11-08       Impact factor: 11.205

2.  An insight into the active site of a type I DNA topoisomerase from the kinetoplastid protozoan Leishmania donovani.

Authors:  Aditi Das; Chhabinath Mandal; Arindam Dasgupta; Tanushri Sengupta; Hemanta K Majumder
Journal:  Nucleic Acids Res       Date:  2002-02-01       Impact factor: 16.971

3.  An ab initio quantum mechanics calculation that correlates with ligand orientation and DNA cleavage site selectivity in camptothecin-DNA-topoisomerase I ternary cleavage complexes.

Authors:  Xiangshu Xiao; Mark Cushman
Journal:  J Am Chem Soc       Date:  2005-07-20       Impact factor: 15.419

4.  A theoretical study of some new analogues of the anti-cancer drug camptothecin.

Authors:  Nihar R Jena; Phool C Mishra
Journal:  J Mol Model       Date:  2006-10-06       Impact factor: 1.810

5.  Human topoisomerase I poisoning: docking protoberberines into a structure-based binding site model.

Authors:  Viktor Kettmann; Daniela Kost'álová; Hans-Dieter Höltje
Journal:  J Comput Aided Mol Des       Date:  2005-06-27       Impact factor: 3.686

6.  AID-induced decrease in topoisomerase 1 induces DNA structural alteration and DNA cleavage for class switch recombination.

Authors:  Maki Kobayashi; Masatoshi Aida; Hitoshi Nagaoka; Nasim A Begum; Yoko Kitawaki; Mikiyo Nakata; Andre Stanlie; Tomomitsu Doi; Lucia Kato; Il-mi Okazaki; Reiko Shinkura; Masamichi Muramatsu; Kazuo Kinoshita; Tasuku Honjo
Journal:  Proc Natl Acad Sci U S A       Date:  2009-12-11       Impact factor: 11.205

7.  Spatial organization of topoisomerase I-mediated DNA cleavage induced by camptothecin-oligonucleotide conjugates.

Authors:  Paola B Arimondo; Stéphane Angenault; Ludovic Halby; Alexandre Boutorine; Frédéric Schmidt; Claude Monneret; Thérèse Garestier; Jian-Sheng Sun; Christian Bailly; Claude Hélène
Journal:  Nucleic Acids Res       Date:  2003-07-15       Impact factor: 16.971

Review 8.  Camptothecins: a review of their chemotherapeutic potential.

Authors:  Hulya Ulukan; Peter W Swaan
Journal:  Drugs       Date:  2002       Impact factor: 9.546

Review 9.  Distinct and overlapping functions of the cullin E3 ligase scaffolding proteins CUL4A and CUL4B.

Authors:  Jeffrey Hannah; Pengbo Zhou
Journal:  Gene       Date:  2015-09-03       Impact factor: 3.688

10.  Evaluation of two models for human topoisomerase I interaction with dsDNA and camptothecin derivatives.

Authors:  Gary S Laco
Journal:  PLoS One       Date:  2011-08-30       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.